Pfizer has announced a strategic shift aimed at achieving growth beyond 2028, primarily through the development of new treatments for obesity and cancer.
The company is placing significant emphasis on innovative drug development in these areas, which could have a substantial impact on the market.
As Pfizer navigates this transition, the success of these new drugs will be crucial for its long-term growth strategy.